

10550196 - GAU: 1654  
Equivalent of Form PTO/SB/08a (07-09)

Equivalent of Form PTO/SB/08a (07-09)

Substitute for form 1449/PTO  <div style="text-align: center;"> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i> </div>				<b>Complete if Known</b>	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
				Attorney Docket Number	1694.0610001/JMC/THN
Sheet	1	of	1		

## U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

1125084 1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

5

Application Number

10/550,196

Filing Date

January 12, 2007

First Named Inventor

Madeleine M. Joullie

Art Unit

1654

Examiner Name

CORDERO GARCIA, MARCELA  
M.

Attorney Docket Number

1694.0610001/JMC/THN

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Bundgaard, H., <i>Design of Prodrugs</i> pp. 7-9, 21-24, Elsevier Science Publishers B.V., The Netherlands (1985)	
	NPL2	Depenbrock, <i>et al.</i> , "In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells," <i>Brit. J. Cancer</i> 78:739-744, Cancer Research Campaign, UK (1998)	
	NPL3	Grubb, <i>et al.</i> , "Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described," <i>Biochem. Biophys. Res. Commun.</i> 215:1130-1136, Academic Press, Inc., United States (1995)	
	NPL4	Johnson, <i>et al.</i> , "Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells," <i>FEBS Lett.</i> 383:1-5, Federation of European Biochemical Societies, UK (1996)	
	NPL5	Johnson, <i>et al.</i> , "Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: Evidence for the possible involvement of FK506-binding protein 25," <i>Immunol. Cell Biol.</i> 77:242-248, Nature Publishing Group, United States (1999)	
	NPL6	Johnson, <i>et al.</i> , "Unspecific Activation of Caspases During the Induction of Aapoptosis by Didemnin B in Human Cell Lines," <i>J. Cell. Biochem.</i> 72:269-278, Wiley-Liss, Inc., United States (1999)	
	NPL7	Li, <i>et al.</i> , "Total Synthesis and Structural Investigations of Didemnins A, B, and C," <i>J. Am. Chem. Soc.</i> 112:7659-7672, American Chemical Society, United States (1990)	
	NPL8	Liang, <i>et al.</i> , "The First Total Synthesis of (-)-Tamandarin A," <i>Org. Lett.</i> 1:1319-1322, American Chemical Society, United States (1999)	
	NPL9	Liang, <i>et al.</i> , "Total Synthesis of [(2S)-Hiv <sup>2</sup> ]Didemnin M," <i>J. Org. Chem.</i> 65:4762-4765, American Chemical Society, United States (2000)	
	NPL10	Liang, <i>et al.</i> , "Total Syntheses and Biological Investigations of Tamandarins A and B and Tamandarin A Analogs," <i>J. Am. Chem. Soc.</i> 123:4469-4474, American Chemical Society, United States (2001)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	2	of	5	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	NPL11	MacLean, <i>et al.</i> , "Glossary of Terms Used in Combinatorial Chemistry," <i>Pure Appl. Chem.</i> 71:2349-2365, IUPAC, United States (1999)		
	NPL12	Petit & Larcheveque, "Ethyl Glycidate from (S)-Serine; Ethyl (R)-(+)-2,3-Epoxypropanoate (Oxiranecarboxylic acid, ethyl ester, (R)-)," <i>Organic Syntheses vol 75</i> , pp. 37-44, ed. Amos B. Smith, III, John Wiley & Sons, Inc, United States (1998)		
	NPL13	Pfizenmayer, <i>et al.</i> , "SYNTHESIS AND BIOLOGICAL ACTIVITY OF [Tic <sup>5</sup> ] DIDEMNIN B," <i>Bioorg. Med. Chem. Lett.</i> 8:3653-3656, Elsevier Science Ltd., UK (1998)		
	NPL14	Sakai, <i>et al.</i> , "Structure-Activity Relationships of the Didemnins <sup>1,2</sup> ," <i>J. Med. Chem.</i> 39:2819-2834, American Chemical Society, United States (1996)		
	NPL15	Skehan, <i>et al.</i> , "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <i>J. Natl. Cancer Inst.</i> 82:1107-1112, Oxford University Press, United States (1990)		
	NPL16	International Search Report for International Application No. PCT/US04/08275, United States Patent and Trademark Office, United States, mailed on August 9, 2005, published October 6, 2005.		
	NPL17	Nakamura, <i>et al.</i> , "Dehydrooligopeptides. XVII. Practical Synthesis of All of the Diastereomers of N,N-Protected 2,3-Diaminobutanoic Acids from L- and D-Threonine Derivatives," <i>Bull. Chem. Soc. Jpn</i> 68:1369-1377, The Chemical Society of Japan, Japan (1995)		
	NPL18	Sifferlen, T., <i>et al.</i> , "β-Thiopeptides: Synthesis, NMR Solution Structure, CD Spectra and Photochemistry," <i>Helv. Chim. Acta</i> 82:2067-2093, Neue Schweizerische Chemische Gesellschaft, Switzerland (1999)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	3	of	5	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL19	Shalaby, M.A., <i>et al.</i> , "Thiopeptide Synthesis. $\alpha$ -Amino Thionoacid Derivatives of Nitrobenzotriazole as Thioacylating Agents," <i>J. Org. Chem.</i> 61:9045-9048, American Chemical Society, United States (1996)	
	NPL20	Sakai, R., <i>et al.</i> , "Seven New Didemnins from the Marine Tunicate <i>Trididemnum solidum</i> ," <i>J. Am. Chem. Soc.</i> 117:3734-3748, American Chemical Society, United States (1995)	
	NPL21	Hossain, M. B., <i>et al.</i> , "Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide," <i>Proc. Natl. Acad. Sci. USA</i> 85:4118-4122, National Academy of Sciences, United States (1988)	
	NPL22	Roush, W.R., <i>et al.</i> , "Design, Synthesis and Evaluation of D-Homophenylalanyl Epoxysuccinate Inhibitors of the Trypanosomal Cysteine Protease Cruzain," <i>Tetrahedron</i> 56:9747-9762, Elsevier Science Ltd., UK (2000)	
	NPL23	Armstrong, R.N., "Nucleophilic Epoxide Openings," <i>Comprehensive Natural Products Chemistry</i> vol 5, pp. 51-70, ed. C. Dale Poulter, Elsevier Science, Ltd., UK (1999)	
	NPL24	Wróblewski, A.E. & Balcerzak, K.B., "Synthesis of diethyl (1R,2R)- and (1S,2R)-3-acetamido-1,2-dihydroxypropylphosphonates," <i>Tetrahedron: Asymmetry</i> 13:845-850, Elsevier Science Ltd., UK (2002)	
	NPL25	Lindberg, J., <i>et al.</i> , "Efficient Synthesis of Phospholipids from Glycidyl Phosphates," <i>J. Org. Chem.</i> 67:194-199, American Chemical Society, United States (2002)	
	NPL26	Sata, N.U., <i>et al.</i> , "Synthesis of all isomers of pulcherrimine, a bitter principle in the sea urchin ovary," <i>Tetrahedron Letters</i> 43:115-118, Elsevier Science Ltd., UK (2002)	
	NPL27	Kwon, S. J. & Ko, S.Y., "Synthesis of statine employing a general <i>syn</i> -amino alcohol building block," <i>Tetrahedron Letters</i> 43:639-641, Elsevier Science Ltd., UK (2002)	
	NPL28	Koviach, J. L., <i>et al.</i> , "Design and Synthesis of Conformationally Constrained Glycosylated Amino Acids," <i>J. Org. Chem.</i> 66:2318-2326, American Chemical Society, United States (2001)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	4	of	5	Attorney Docket Number	1694.0610001/JMC/THN
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	NPL29	Gravier-Pelletier, C., <i>et al.</i> , "Liposidomycins - Synthetic Studies Towards the Ribosyldiazepanone Moiety," <i>Eur. J. Org. Chem.</i> 16:3089-3096, WILEY-VCH Verlag GmbH, Germany (2001)			
	NPL30	Bardi, R., <i>et al.</i> , "Molecular and Crystal Structures of Three Monothiated Analogues of the Terminally Blocked Ala-Aib-Ala Sequence of Peptaibol Antibiotics," <i>Bipolymers</i> 27:747-761, John Wiley & Sons, Inc., United States (1988)			
	NPL31	Meyer, J.-P., <i>et al.</i> , "Synthesis Using a Fmoc-Based Strategy and Biological Activities of Some Reduced Peptide Bond Pseudopeptide Analogues of Dynorphin A <sup>1</sup> ," <i>J. Med. Chem.</i> 38:3462-3468, American Chemical Society, United States (1995)			
	NPL32	Tran, T. T., <i>et al.</i> , "Effects of Thioamide Substitutions on the Conformation and Stability of $\alpha$ - and $3_{10}$ -Helices," <i>J. Am. Chem. Soc.</i> 124:5222-5230, American Chemical Society, United States (2002)			
	NPL33	Gauthier, J.Y & Lebel, H., "A remarkably simple conversion of nitriles to thioamides," <i>Phosphorus, Sulfur, and Silicon</i> 95-96:325-326, OPA Amsterdam B.V., Holland (1994)			
	NPL34	Davidsen, S.K., <i>et al.</i> , "Di-tert-butyl N-Acylimidodicarbonates as Isolable Acylating Agents: Mild Conversion of Primary Carboxamides to Substituted Amides," <i>J. Org. Chem.</i> 56:5482-5485, American Chemical Society, United States (1991)			
	NPL35	Pozdnev, V.F., "Activation of carboxylic acids by pyrocarbonates. Application of di-tert-butyl pyrocarbonate as condensing reagent in the synthesis of amides of protected amino acids and peptides," <i>Tetrahedron Letters</i> 36:7115-7118, Elsevier Science Ltd., UK (1995)			
	NPL36	Rinehart, Jr., K. L., <i>et al.</i> , "Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate," <i>Science</i> 212:933-935, AAAS, United States (1981)			
	NPL37	Supplementary Partial European Search Report, Application No. EP 01924886.3, 07-12-2004			
	NPL38	Abou-Mansour, E., <i>et al.</i> , "[Tyr <sup>5</sup> ]didemnin B and [D-Pro <sup>4</sup> ]didemnin B ; Two New Natural Didemnins with a Modified Macrocyclic," <i>Tetrahedron</i> 51:12591-12600, Elsevier Science Ltd., UK (1995)			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	5	of	5	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	NPL39	Rose, N.G.W., <i>et al.</i> , "Synthesis of enantiomerically enriched $\beta,\gamma$ -unsaturated- $\alpha$ -amino acids," <i>Tetrahedron</i> 57:1497-1507, Elsevier Science Ltd., UK (2001)		
	NPL40	Blaskovich, M. A., <i>et al.</i> , "Stereoselective Synthesis of <i>Threo</i> and <i>Erythro</i> $\beta$ -Hydroxy and $\beta$ -Disubstituted- $\beta$ -Hydroxy $\alpha$ -Amino Acids," <i>J. Org. Chem.</i> 63:3631-3646, American Chemical Society, United States (1998)		
	NPL41	Spero, D.M. & Kapadia, S.R., "Enantioselective Synthesis of $\alpha,\alpha$ -Disubstituted Amino Acid Derivatives <i>via</i> Enzymatic Resolution: Preparation of a Thiazolyl-Substituted $\alpha$ -Methyl $\alpha$ -Benzyl Amine," <i>J. Org. Chem.</i> 61:7398-7401, American Chemical Society, United States (1996)		
	NPL42	Adrio, J., <i>et al.</i> , "Total Synthesis and Biological Evaluation of Tamandarin B Analogues," <i>J. Org. Chem.</i> 72:5129-5138, American Chemical Society, United States (2007)		
	NPL43	Pfizenmayer, A.J., <i>et al.</i> , "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF [ <i>N</i> -MeLeu <sup>5</sup> ]- and [ <i>N</i> -MePhe <sup>5</sup> ]-DIDEMNIN B," <i>Tetrahedron</i> 55:313-334, Elsevier Science Ltd., UK (1999)		
	NPL44	Schmidt, U., <i>et al.</i> , "Synthesis and cytostatic activities of didemnin derivatives*," <i>Journal of Peptide Research</i> 54:146-161, Munksgaard International Publishers Ltd, Denmark (1999)		
	NPL45	Grieco, P.A. & Bahsas, A., "Immonium Ion Based Synthetic Methodology: A Novel Method for the N-Methylation of Dipeptides and Amino Acid Derivatives <i>via</i> Retro Aza Diels-Alder Reactions," <i>J. Org. Chem.</i> 52:5746-5749, American Chemical Society, United States (1987)		
	NPL46	Wipf, P & Venkatraman, S., "Total Synthesis of (-)-Muscoride A," <i>J. Org. Chem.</i> 61:6517-6522, American Chemical Society, United States (1996)		
	NPL47	Kim, H.-O., <i>et al.</i> , "Copper(I)-Promoted Condensation of $\alpha$ -Amino Acids with $\beta$ -Keto Thio Esters: Synthesis of N-Acylated L-Leucine Derivatives Containing (S)-4-Hydroxy-5-methyl- and (S)-4-Hydroxy-2,5-dimethyl-3-oxohexanoic Acid," <i>J. Org. Chem.</i> 52:4531-4536, American Chemical Society, United States (1987)		

1125294\_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature	/Marcela Cordero Garcia/	Date Considered	11/15/2010
--------------------	--------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.